Alnylam awaits FDA decisions on Amvuttra & Fitusiran next month, poised to boost revenue, profitability, and share growth.

As Alnylam Pharmaceuticals approaches its highly anticipated March 23 FDA decision date for a potential expansion of Amvuttra to treat patients in an increasingly competitive indication—transthyret | ...

Q4 2024 Management View CEO Yvonne Greenstreet highlighted 2024 as a strong year with $1.6 billion in net product revenues, achieving the upper end of the revised guidance. She emphasized the positive ...

BridgeBio could be an acquisition target, but current financial challenges and competition suggest a "Hold" rating until ...

Amvuttra is the medicine that can reduce the amount of abnormal proteins in your body to help decrease symptoms and possibly prevent further nerve damage. Hereditary transthyretin-mediated ...

Alnylam Pharmaceuticals Inc (ALNY) reports robust financial performance with a 33% revenue growth and outlines strategic ...

It has received multiple approvals for RNAi-based medicines such as Onpattro and Amvuttra, both of which are leading in the company's successful commercialization strategy. Under Alnylam’s ...

Like other drugs, Amvuttra (vutrisiran) can cause side effects, such as difficulty breathing and low vitamin A levels. If you can’t tolerate side effects of Amvuttra, talk with your doctor.

Amvuttra (vutrisiran) is a prescription drug that’s used to treat nerve damage related to a rare genetic condition. Amvuttra is given as an injection under your skin by a healthcare professional.

Amvuttra (vutrisiran), as well as for Givlaari (givosiran) and Oxlumo (lumasiran). In the past three months, shares of Alnylam have gained 12.5% compared with the industry’s growth of 7.7%.